Upadacitinib is a selective Janus kinase (JAK) inhibitor used to treat moderate to severe autoimmune inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative… Read more

![Chemical structure of Benzyl (3S,4S)-3-(N-(tert-butoxycarbonyl)-N-(5-tosyl-5H-pyrrolo[2,3-b]pyrazin-2-yl)glycyl)-4-ethylpyrrolidine-1-carboxylate](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F2768445-17-4-Benzyl-3S4S-3-N-tert-butoxycarbonyl-N-5-tosyl-5H-pyrrolo23-bpyrazin-2-ylglycyl-4-ethylpyrrolidine-1-carboxylate.png&w=3840&q=75)

![Chemical structure of Benzyl (3S,4S)-3-ethyl-4-(3-tosyl-3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)pyrrolidine-1-carboxylate](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F2270173-65-2-Benzyl-3S4S-3-ethyl-4-3-tosyl-3H-imidazo12-apyrrolo23-epyrazin-8-ylpyrrolidine-1-carboxylate.png&w=3840&q=75)

![Chemical structure of bis(5-Tosyl-5H-pyrrolo[2,3-b]pyrazin-2-yl)amine](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2Fbis5-Tosyl-5H-pyrrolo23-bpyrazin-2-ylamine.png&w=3840&q=75)
![Chemical structure of Isopropyl (5-tosyl-5H-pyrrolo[2,3-b]pyrazin-2-yl)carbamate](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2FIsopropyl-5-tosyl-5H-pyrrolo23-bpyrazin-2-ylcarbamate.png&w=3840&q=75)

![Chemical structure of Methyl (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)pyrrolidine-1-carboxylate](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2FMethyl-3S4R-3-ethyl-4-3H-imidazo12-apyrrolo23-epyrazin-8-ylpyrrolidine-1-carboxylate.png&w=3840&q=75)
![Chemical structure of Methyl (5-tosyl-5H-pyrrolo[2,3-b]pyrazin-2-yl)carbamate](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F2408790-02-1-Methyl-5-tosyl-5H-pyrrolo23-bpyrazin-2-ylcarbamate.png&w=3840&q=75)
![Chemical structure of Methyl 5H-pyrrolo[2,3-b]pyrazine-2-carboxylate](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F1363381-89-8-Methyl-5H-pyrrolo23-bpyrazine-2-carboxylate.png&w=3840&q=75)





![Chemical structure of rel-(3R,4S)-3-Ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F1831899-72-9-rel-3R4S-3-Ethyl-4-3H-imidazo12-apyrrolo23-epyrazin-8-yl-N-222-trifluoroethylpyrrolidine-1-carboxamide.png&w=3840&q=75)


![Chemical structure of tert-Butyl (5-tosyl-5H-pyrrolo[2,3-b]pyrazin-2-yl)carbamate](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F1201187-44-1-tert-Butyl-5-tosyl-5H-pyrrolo23-bpyrazin-2-ylcarbamate.png&w=3840&q=75)






















Upadacitinib is a selective Janus kinase (JAK) inhibitor used to treat moderate to severe autoimmune inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, Crohn’s disease, ankylosing spondylitis, and giant cell arteritis. In pharmaceutical development and manufacturing, Upadacitinib reference standards are essential tools for ensuring product safety, therapeutic efficacy, and regulatory compliance. These highly characterized materials allow laboratories to conduct precise impurity profiling, identifying process-related compounds, synthetic intermediates, and degradation products that may arise during formulation or storage. Furthermore, stable isotope labelled compounds are utilized as internal standards in analytical testing and method validation to provide high-accuracy quantitative data. By supporting robust quality control and stability studies in accordance with ICH guidelines, these reference standards ensure that every batch of the drug substance meets the necessary identity, strength, and purity specifications required for clinical use.